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severe male subpopulation was analyzed (P = 0.0004). Finally, the relative risk of the concurrent presence of both 5-HTTLPR and MAOA less efficient copies was 2.75 for male gamblers (CI: 1.36-5.54; P Ͻ 0.01) and even higher for the more severe male gamblers (RR = 3.41; CI: 1.69-6.86; P Ͻ 0.001). Previously, we have analysed other candidate genes using the same set of patients and controls used in this work. We have reported positive associations for the D4 and D2 dopamine receptor genes, 4, 5 and for the serotonin transporter (5-HTT) gene, 3 and no association for MAO-B and tyrosine hydroxylase polymorphisms (unpublished data). 1 Although others have reported similar associations, [6] [7] [8] in other cases our data have not been replicated and different genes have been associated with PG. 8, 9 These results could be in agreement with the existence of different models for this polygenic disorder in such a way that different sets of genes are altered in different sets of pathological gamblers.
The aggregation of findings in the MAO-A and 5-HTT genes suggests that the concurrent presence of two of their functional variants plays an important role in the etiology of this disorder among the male patients analyzed in this study. Therefore, our results indicate that MAO-A and 5-HTT regulatory polymorphisms may contribute simultaneously to part of the genetic dimension of PG, although, and because of the genetic heterogeneity of this disorder, this may not be a universal finding for all the cases of PG. SIR -Anxiety disorders are common mental disorders, encompassing a group of psychiatric conditions that share extreme anxiety as the primary disturbance in mood or emotional tone. Those include generalized anxiety disorder, panic disorder (PD), phobias, obsessive-compulsive disorder and post-traumatic stress disorder. PD arises when several apparently spontaneous panic attacks lead to a persistent concern about future attacks, worry about their implications or changes in behavior. The prevalence of PD in the general population is between 1.4 and 3%.
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There is neuroanatomical, neurophysiological, neurochemical and behavioral preclinical evidence to suggest that the development of anxiety or fear relates, in part, to increased brain noradrenergic neuronal activity. Pharmacological or electrical activation of noradrenergic neurons of the locus coeruleus (LC), the major noradrenergic nucleus in brain, has anxiogenic effects in nonhuman primates, and elevated LC neuron firing is associated with anxiety or fear responses. 2, 3 Several studies have proven a genetic background contributing to the etiology of PD 4, 5 and different genes and genomic regions have been proposed as candidates. The identification of a genomic duplication (DUP25) 6 in a large proportion of patients diagnosed with PD and phobic disorders has shed new light onto the genetic basis of this complex disease. Based on their expression pattern and their function in the nervous system, several genes within the DUP25 region can be considered as candidates to participate in the pathophysiology of PD.
One of those candidates is NTRK3, which maps to the 15q25 region and encodes the high-affinity receptor for neurotrophin 3 (NT-3). Neurotrophins and their receptors play a critical role in the development and plasticity of both the central and peripheral nervous system. Abnormal levels of neurotrophins have been postulated as a possible factor in the cellular alterations observed in certain brain areas of patients suffering from different psychiatric disorders. 7, 8 Different neurotrophic factors and their receptors are expressed in the LC during the central nervous system development and in the adult, but, unlike in other regions of the brain, the only expressed receptor for NT-3 in the LC is NTRK3. Thus, we hypothesize that the overexpression of NTRK3 in the LC could cause modifications in the morphology or functionality of this brainstem nucleus. PD, panic disorder. PD samples were compared to a gender and age-matched control sample. The newly identified allele was named '2' while allele '1' corresponds to the originally published sequence. A 2 analysis was performed to compare the distribution of the alleles and genotypes between the two samples. All individuals gave their written consent to participate in the study. One and two degrees of freedom were considered respectively when comparing alleles and genotypes between the two samples. The two-sided P value was obtained by a Fisher's exact test.
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We first searched for SNPs in the NTRK3 gene that could be involved in patophysiology of PD. A collection of primer pairs was designed to amplify each of the 20 exons and the 5′ flanking region of the NTRK3 gene. The fragments were amplified by the polymerase chain reaction using 100 ng of DNA template, and electrophoresed at 4°C on a 10% or 12% acrylamide/bisacrylamide gel for the SSCP analysis. Gels were silver stained and those fragments showing an abnormal pattern were sequenced using a commercial reaction kit on an ABI 377 automatic sequencer.
Four new SNPs named IN3, EX5, EX12 and PromII were identified and confirmed by direct sequencing. None of them affects the amino acidic composition of the protein. IN3 polymorphism corresponds to a T/C transition at position 420 of the exon 3 (GenBank AJ224523), while EX5 and EX12 variants are a C/T transition at position 665 and a G/C transversion at 1643 (NM 002530), respectively. Prom II corresponds to an A/G transition at position −1144 of the NTRK3 gene (NM 002530). The in silico analysis of the NT-3 promoter sequence showed that it might alter recognition sequences for different transcription factors.
An association study was driven to test whether any of those SNPs could be associated with panic disorder. A total of 59 unrelated consecutive outpatients of both sexes and older than 18 were diagnosed of panic disorder with or without agoraphobia by the SCID-DSM-III-R interview at the Anxiety Unit of the Hospital del Mar. The control sample consisted of 86 unrelated individuals from the general population not tested for any mental disorder, matched to the PD sample by gender and age.
None of the polymorphisms in the coding region was significantly associated with panic disorder. Nevertheless, allele 2 of the SNP in the 5′UTR-region of NTRK3 was found to be moderate, but significantly associated with PD ( 2 = 5.14, 1 df, 2 P = 0.02), suggesting a tendency to heterozygosity in PD (Table 1) .
To date, most of the efforts to elucidate the genetic factors underlying PD have been focused on genes whose products are involved in its pathophysiology or that could mediate the biological effects caused by panicogenic agents. Changes in the expression or function of NTRK3 may alter synaptic plasticity through the change of local trophic support. This could possibly cause the abnormal release rates of certain neurotransmitters, like NA, in target areas that lead to the alteration of the individual's arousal threshold. The SNP we found more frequently in the PD sample is located in the putative promoter region of the gene, giving support to the hypothesis that the alteration of the normal amounts of messenger could participate in the pathophysiology of PD. Since most samples used in our study also have DUP25, the 5′ UTR SNP described above might be one of several genetic factors that contribute to modify the development and severity of panic disorder. 
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